Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A Hochhaus

Early Molecular and Cytogenetic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML)

Leukemia

English

Omacetaxine Mepesuccinate Prevents Cytokine-Dependent Resistance to Nilotinib in Vitro: Potential Role of the Common Β-Subunit C of Cytokine Receptors

English

Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up

English

Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (pDC) Predicts Risk of Disease Recurrence After Treatment Discontinuation in CML

English

Long-Term Outcome of Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Randomized Comparison of Stem Cell Transplantation With Drug Treatment

English

Management of Adverse Events Associated With Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

English

European LeukemiaNet Recommendations for the Management and Avoidance of Adverse Events of Treatment in Chronic Myeloid Leukaemia

English

Rates of Peripheral Arterial Occlusive Disease in Patients With Chronic Myeloid Leukemia in the Chronic Phase Treated With Imatinib, Nilotinib, or Non-Tyrosine Kinase Therapy: A Retrospective Cohort Analysis

English

A Certified Plasmid Reference Material for the Standardisation of BCR–ABL1 mRNA Quantification by Real-Time Quantitative PCR

English

Capecitabine-Associated Hand–foot–skin Reaction Is an Independent Clinical Predictor of Improved Survival in Patients With Colorectal Cancer

British Journal of Cancer

Cancer Research

Oncology

2012

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A Hochhaus

Early Molecular and Cytogenetic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML)

Omacetaxine Mepesuccinate Prevents Cytokine-Dependent Resistance to Nilotinib in Vitro: Potential Role of the Common Β-Subunit C of Cytokine Receptors

Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up

Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (pDC) Predicts Risk of Disease Recurrence After Treatment Discontinuation in CML

Long-Term Outcome of Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Randomized Comparison of Stem Cell Transplantation With Drug Treatment

Management of Adverse Events Associated With Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

European LeukemiaNet Recommendations for the Management and Avoidance of Adverse Events of Treatment in Chronic Myeloid Leukaemia

Rates of Peripheral Arterial Occlusive Disease in Patients With Chronic Myeloid Leukemia in the Chronic Phase Treated With Imatinib, Nilotinib, or Non-Tyrosine Kinase Therapy: A Retrospective Cohort Analysis

A Certified Plasmid Reference Material for the Standardisation of BCR–ABL1 mRNA Quantification by Real-Time Quantitative PCR

Capecitabine-Associated Hand–foot–skin Reaction Is an Independent Clinical Predictor of Improved Survival in Patients With Colorectal Cancer